Malignant Melanoma | Pharmacor | G7 | 2014
The poor prognosis of advanced malignant melanoma (melanoma) patients means that there is a significant need for effective therapies to treat patients in this indication and a large commercial opportunity for drug developers. Immunotherapy treatments have actively been researched in melanoma and have received approval. Furthermore, the launch of BRAF and MEK inhibitors for BRAF-mutation-positive melanoma has segmented the market according to patients’ BRAF-mutation status, a trend that looks set to continue. With the entry of novel immunotherapies and BRAF and MEK inhibitors, the melanoma market is set to become increasingly competitive as agents vie for patient share.
Related Market Assessment Reports
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Malignant Melanoma (US)
Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…
Report
Malignant Melanoma – Current Treatment – Current Treatment: Physician Insights – Malignant Melanoma (US)
Disease stage, primary tumor resectability, and BRAF mutation status are some of the key parameters influencing the treatment of malignant melanoma. For patients with BRAF mutations, BRAF/MEK…
